Medscape, July 9, 2023:Medscape quotes experts disagreeing about what age (40? 50? to start mammograms and we point out that the science suggests different guidelines based on race and risk. Radiologists suggest Black women start at age 35, which would means $$$ for the radiologists but would do more harm than good for most women. USPSTF recommendations raise concerns about costs, accuracy, timing, and ensuring that abnormal mammograms result in biopsies to learn if treatment is needed.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Alzheimer’s Drug Safety Hinges on Doctors Heeding FDA Warning
Bloomberg Law News, July 12, 2023: NCHR says the FDA black box warnings about brain swelling and bleeding and other cautions about who is most likely to be harmed by Alzheimer’s drug Leqembi will help protect patients with mild cognitive impairment, but only if their doctors pay attention and accurately discuss the risks vs. uncertain benefits with patients and family members.
Read More »No more FDA adcomm votes? Reforms brew as new research highlights decline in meetings
Endpoints News, July 7, 2023: FDA wants to revamp its Advisory Committee meetings but will they make them better or worse? The votes aren’t the problem. We explain that the conflicts of interest of committee members is “outrageous.”
Read More »Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic
STAT News, July 5, 2023: Novo Nordisk gave doctors 450,000 free restaurant meals and snacks in 2022 while promoting drugs like Ozempic for weight loss. One doctor got 183 meals. Some got free trips to Paris or Hawaii. Can those doctors be objective about the risks and benefits of the drugs?
Read More »Alzheimer’s Patient Registry Raising Questions as Drug OK Nears
Bloomberg News, June 29, 2023: If Leqembi is approved for very early Alzheimer’s, CMS and NCHR explain how the Medicare registry will help patients make informed decisions about whether the benefits are likely to outweigh the risks for them for this expensive and risky treatment. But PhRMA and aligned patient groups complain.
Read More »